The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high ...

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

Pregnant women's attitudes towards receiving the respiratory syncytial virus (RSV) vaccine to protect their newborn babies ...

Some assume pneumonia is an inevitable consequence of ageing, while others may not realise they are at risk, says infectious ...

Clinical trials have shown that the RSV vaccine reduces symptoms by around 80 per cent, significantly lowering the risk of ...

Roughly 8000 Brits died from respiratory syncytial virus infections last year, with tens of thousands likely clogging up ...

The Allan Labor Government is backing a new study to boost the number of expectant mothers having the Respiratory Syncytial Virus (RSV) immunisation ...

Another vaccine maker, Moderna’s MRNA RSV vaccine – mResvia – was approved last year by the FDA and the European Commission to prevent RSV-LRTD in older adults aged 60 years and above.

The Department of Health has announced that the jab would be more widely available as part of a wider package of preventative ...

The U.S. has tallied 8,077 cases of whooping cough in 2025, compared with 3,847 cases in the same period last year, federal ...

At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted on recommendations for several ...

Studies have shown that even as little as $1 in cost can be a disincentive to accessing preventive care, Mason said. "When ...